Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention KOMZIFTI, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 3.6 for the same window.
Last mentioned: Mar 6, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention KOMZIFTI, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 3.6 for the same window. The 5 average consequence score is below the beat benchmark of 5.8 in the same window. We currently track 1 Healthcare story that mention TULSA-PRO, all published on March 6, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering TULSA-PRO. Shared-story counts are live from our verified record — not editorial picks.
Kura Oncology and Profound Medical reported Q4 2025 results, highlighting a critical transition period as they navigate commercial launches and reimbursement hurdles. While both firms faced revenue headwinds, Kura's $7 billion AML opportunity and Profound's significant EPS beat underscore a shifting landscape in oncology and incision-less surgery.
Source: themarketsdaily.com · finance.yahoo.com
TULSA-PRO is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
